Braveheart Bio is a Bay Area–based biopharmaceutical company pioneering best-in-class therapies for cardiovascular disease. Our lead program is a next-generation myosin inhibitor, licensed from Hengrui Pharma, being developed to transform the treatment of hypertrophic cardiomyopathy (HCM)—the most common inherited cardiac disease. Currently in Phase 3 clinical development in China for the more common obstructive form of HCM, our candidate has demonstrated a compelling clinical profile that may position it as a best-in-class therapy with meaningful differentiation. With a proven leadership team, a strong financial foundation, and a high-value late-stage asset, Braveheart Bio represents an outstanding opportunity for ambitious, mission-driven professionals to make a tangible impact in a high-profile and rapidly evolving therapeutic area. The Director of Quality will serve as a quality leader for Braveheart Bio and will be responsible for manufacturing quality oversight, and inspection readiness for our late-stage clinical program in hypertrophic cardiomyopathy (HCM). Reporting to the Vice President, Quality, this individual will execute the manufacturing quality oversight framework for investigational and commercial product to support global Phase 3 execution and to prepare for future regulatory submissions and commercialization activities. This leader will partner closely with Manufacturing, Regulatory, partners, and CDMOs to ensure best-in-class quality oversight across all programs. As the company grows, this position may include building a small team. This is a hands-on, foundational role for a lean, fast-moving biotech entering late-stage development.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Director